GSK2857916 ( DrugBank: - )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 28 | 全身性アミロイドーシス | 5 |
28. 全身性アミロイドーシス
臨床試験数 : 261 / 薬物数 : 276 - (DrugBank : 81) / 標的遺伝子数 : 68 - 標的パスウェイ数 : 178
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2020-004001-32-NL (EUCTR) | 24/06/2021 | 29/01/2021 | Belantamab Mafodotin in patients with relapsed or refractory AL amyloidosis | A phase 2 study of Belantamab Mafodotin in patients with relapsed or refractory AL amyloidosis | relapsed or refractory AL amyloidosis MedDRA version: 20.0;Level: PT;Classification code 10002022;Term: Amyloidosis;System Organ Class: 10021428 - Immune system disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Name: belantamab mafodotin Product Code: GSK2857916 INN or Proposed INN: belantamab mafodotin | European Myeloma Network – EMN | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 36 | Phase 2 | France;Greece;Germany;Netherlands;United Kingdom;Italy | ||
| 2 | EUCTR2020-004001-32-IT (EUCTR) | 03/05/2021 | 02/08/2021 | Belantamab Mafodotin in patients with relapsed or refractory AL amyloidosis | A phase 2 study of Belantamab Mafodotin in patients with relapsed or refractory AL amyloidosis. - EMN27 | Relapsed or refractory AL amyloidosis. MedDRA version: 20.0;Level: PT;Classification code 10002022;Term: Amyloidosis;System Organ Class: 10021428 - Immune system disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Name: Belantamab mafodotin Product Code: [GSK2857916] INN or Proposed INN: belantamab mafodotin | STICHTING EUROPEAN MYELOMA NETWORK | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 36 | Phase 2 | France;Greece;Netherlands;Germany;United Kingdom;Italy | ||
| 3 | EUCTR2020-004001-32-DE (EUCTR) | 27/04/2021 | 04/12/2020 | Belantamab Mafodotin in patients with relapsed or refractory AL amyloidosis | A phase 2 study of Belantamab Mafodotin in patients with relapsed or refractory AL amyloidosis | relapsed or refractory AL amyloidosis MedDRA version: 20.0;Level: PT;Classification code 10002022;Term: Amyloidosis;System Organ Class: 10021428 - Immune system disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Name: belantamab mafodotin Product Code: GSK2857916 INN or Proposed INN: belantamab mafodotin | European Myeloma Network – EMN | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 36 | Phase 2 | France;Greece;Netherlands;Germany;United Kingdom;Italy | ||
| 4 | EUCTR2020-004001-32-FR (EUCTR) | 29/01/2021 | 03/12/2020 | Belantamab Mafodotin in patients with relapsed or refractory AL amyloidosis | A phase 2 study of Belantamab Mafodotin in patients with relapsed or refractory AL amyloidosis | relapsed or refractory AL amyloidosis MedDRA version: 20.0;Level: PT;Classification code 10002022;Term: Amyloidosis;System Organ Class: 10021428 - Immune system disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Name: belantamab mafodotin Product Code: GSK2857916 INN or Proposed INN: belantamab mafodotin | European Myeloma Network – EMN | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 36 | Phase 2 | France;Greece;Netherlands;Germany;United Kingdom;Italy | ||
| 5 | EUCTR2020-004001-32-GR (EUCTR) | 15/01/2021 | 04/12/2020 | Belantamab Mafodotin in patients with relapsed or refractory AL amyloidosis | A phase 2 study of Belantamab Mafodotin in patients with relapsed or refractory AL amyloidosis | relapsed or refractory AL amyloidosis MedDRA version: 20.0;Level: PT;Classification code 10002022;Term: Amyloidosis;System Organ Class: 10021428 - Immune system disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Name: belantamab mafodotin Product Code: GSK2857916 INN or Proposed INN: belantamab mafodotin | European Myeloma Network – EMN | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 36 | Phase 2 | France;Greece;Netherlands;Germany;United Kingdom;Italy |